Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d’Ivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Toure, Offianan A, Assi, Serge B, N’Guessan, Tiacoh L, Adji, Gbessi E, Ako, Aristide B, Brou, Marie J, Ehouman, Marie F, Gnamien, Laeticia A, Coulibaly, M’Lanhoro AA, Coulibaly, Baba, Beourou, Sylvain, Bassinka, Issiaka, Soumahoro, Adama, Kadjo, Florence, Tano, Mea A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251865/
https://www.ncbi.nlm.nih.gov/pubmed/25409546
http://dx.doi.org/10.1186/1475-2875-13-439

Ejemplares similares

Ejemplares similares